Profile data is unavailable for this security.
About the company
Biocon Limited is an India-based biopharmaceutical company, which focuses on treating diabetes, cancer and autoimmune diseases. Its segment includes Generics, Biosimilars, Novel Biologics and Research Services. It has developed and commercialized novel biologics, biosimilars, and complex small molecule active pharmaceutical ingredients (APIs) in India and several key global markets, as well as Generic Formulations in the United Sates, Europe and key emerging markets. Its API portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology and other key products. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. It has over five facilities across Bangalore, Hyderabad and Visakhapatnam in India. Its API manufacturing facilities leverage complex technology platforms that range from microbial fermentation, chromatographic purification, chemical synthesis, peptide synthesis and HPAPIs.
- Revenue in INR (TTM)147.66bn
- Net income in INR15.81bn
- Incorporated1978
- Employees3.68k
- LocationBiocon Ltd20th KM, Hosur Road, Electronic City,BANGALORE 560100IndiaIND
- Phone+91 8 028082808
- Fax+91 8 028523423
- Websitehttps://www.biocon.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shanghai Allist Pharmaceuticals Co Ltd | 33.68bn | 12.92bn | 225.50bn | 1.04k | 17.45 | 4.22 | -- | 6.70 | 2.43 | 2.43 | 6.32 | 10.03 | 0.6579 | 3.28 | 10.58 | 2,726,042.00 | 25.24 | 0.6405 | 27.43 | 0.6933 | 94.47 | 96.42 | 38.37 | 2.54 | 7.88 | -- | 0.0003 | 211.88 | 155.14 | 237.34 | 393.54 | -- | 13.53 | -- |
| Genscript Biotech Corp | 84.41bn | -14.80bn | 272.66bn | 7.28k | -- | 2.68 | -- | 3.23 | -0.6517 | -0.6517 | 3.72 | 4.45 | 0.3006 | 9.15 | 7.99 | 1,134,139.00 | -9.68 | -18.34 | -14.76 | -26.15 | 53.63 | 54.68 | -32.19 | -64.91 | 4.06 | -- | 0.1972 | -- | 34.17 | 29.44 | 57.91 | -- | 17.14 | -- |
| Telix Pharmaceuticals Ltd | 36.80bn | 2.80bn | 357.79bn | 234.00 | 125.32 | 15.52 | 111.25 | 9.72 | 0.1497 | 0.1497 | 1.96 | 1.21 | 1.22 | 11.36 | 8.61 | -- | 9.31 | -29.08 | 15.01 | -40.27 | 61.80 | 61.64 | 7.62 | -37.14 | 0.8687 | -- | 0.052 | -- | 213.90 | 381.02 | 105.01 | -- | -- | -- |
| Syngene International Ltd | 34.70bn | 4.92bn | 361.57bn | 6.51k | 73.68 | -- | 39.17 | 10.42 | 12.24 | 12.24 | 86.29 | -- | -- | -- | -- | 5,330,569.00 | -- | 8.62 | -- | 11.43 | 72.89 | 71.13 | 14.19 | 16.22 | -- | 6.36 | -- | -- | 9.26 | 13.83 | 9.82 | 8.99 | -2.62 | 20.11 |
| Sichuan Kelun-Biotech Biophrmctcl Co Ltd | 22.16bn | -2.75bn | 423.43bn | 1.54k | -- | 11.17 | -- | 19.11 | -1.13 | -1.13 | 9.33 | 15.85 | 0.5869 | 9.46 | 18.99 | 1,459,849.00 | -7.28 | -- | -16.56 | -- | 61.81 | -- | -12.40 | -- | 5.59 | -- | 0.0118 | -- | 91.62 | -- | 6.81 | -- | -- | -- |
| Biocon Ltd | 147.66bn | 15.81bn | 432.81bn | 3.68k | 27.38 | -- | 11.93 | 2.93 | 13.20 | 13.20 | 123.37 | -- | -- | -- | -- | 40,114,100.00 | -- | 3.20 | -- | 4.48 | 67.01 | 62.04 | 13.62 | 9.37 | -- | 1.54 | -- | 8.22 | 32.05 | 21.76 | 120.99 | 2.46 | 5.30 | 0.00 |
| WuXi Biologics (Cayman) Inc | 202.10bn | 31.08bn | 540.11bn | 12.44k | 18.09 | 1.13 | 10.13 | 2.67 | 0.6701 | 0.6701 | 4.38 | 10.77 | 0.3163 | 5.35 | 2.80 | 1,478,530.00 | 5.57 | 8.28 | 6.85 | 10.25 | 38.66 | 43.25 | 17.60 | 27.46 | 2.62 | 63.58 | 0.0928 | 0.00 | 11.56 | 46.38 | -23.09 | 40.07 | 20.32 | -- |
| Akeso Inc | 22.13bn | -8.68bn | 594.08bn | 2.82k | -- | 9.63 | -- | 26.85 | -0.9633 | -0.9633 | 2.45 | 6.64 | 0.1925 | 0.3565 | 5.27 | 742,430.80 | -8.18 | -11.59 | -9.19 | -13.87 | 92.50 | -- | -42.50 | -42.49 | 4.43 | -2.16 | 0.3922 | -- | 440.35 | 337.43 | 273.60 | -- | 63.99 | -- |
| PharmaEssentia Corp | 18.11bn | 3.47bn | 647.96bn | 131.00 | 177.23 | 9.51 | 148.46 | 35.78 | 4.09 | 4.09 | 21.42 | 76.26 | 0.2478 | 0.6845 | 4.22 | -- | 4.75 | -16.79 | 5.08 | -19.66 | 87.46 | 76.47 | 19.16 | -79.56 | 12.10 | -- | 0.0408 | -- | 77.15 | 186.97 | 54.62 | -- | 66.34 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Life Insurance Corporation of India (Investment Portfolio)as of 30 Jun 2024 | 59.25m | 4.94% |
| SBI Funds Management Ltd.as of 31 Aug 2024 | 32.03m | 2.67% |
| Kotak Mahindra Asset Management Co. Ltd.as of 31 Aug 2024 | 19.28m | 1.61% |
| Arohi Asset Management Pte Ltd.as of 17 Mar 2023 | 18.95m | 1.58% |
| The Vanguard Group, Inc.as of 04 Sep 2024 | 17.19m | 1.43% |
| Mirae Asset Investment Managers (India) Pvt Ltd.as of 31 Aug 2024 | 9.21m | 0.77% |
| ICICI Prudential Asset Management Co. Ltd.as of 31 Aug 2024 | 6.05m | 0.50% |
| BlackRock Fund Advisorsas of 05 Sep 2024 | 5.91m | 0.49% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Aug 2024 | 5.59m | 0.47% |
| Tata Asset Management Pvt Ltd.as of 31 Aug 2024 | 4.74m | 0.39% |
